Moleculin Biotech (MBRX) Fundamental Analysis: Revenue, Earnings & Valuation

4.07 / 10

Netural

Fundamentally, MBRX scores 4.1/10, indicating moderate health. Strengths include a high interest coverage ratio (35.1) and favorable Asset‑MV, while concerns arise from a low revenue‑MV and modest PB‑ROE. Debt levels are low, but long‑term debt to working capital is modest.

Analysis Checks(8/10)

Revenue-MV

Value-0.11

Score3/3

Weight32.41%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.45%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.70%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value96.26

Score3/3

Weight6.02%

1M Return1.67%

PB-ROE

Value1.04

Score1/3

Weight26.19%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.09

Score1/3

Weight-2.18%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.76%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.18%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.55%

1M Return-1.13%

Asset-MV

Value-0.55

Score2/3

Weight47.93%

1M Return11.12%

Is MBRX undervalued or overvalued?

MBRX scores 4.07/10 on fundamentals and holds a Fair valuation at present. Backed by its -256.84% ROE, 0.00% net margin, -0.37 P/E ratio, 0.83 P/B ratio, and 84.97% earnings growth, these metrics solidify its Netural investment rating.